Home > Insider Trading > Filing (0001209191-22-054201)

Filing Details

Accession Number:: 0001209191-22-054201
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-10-20 17:25:38
Reporting Period:: 2022-10-18

Accepted Time:: 2022-10-20 17:25:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595585	Tricida Inc.	TCDA	Pharmaceutical Preparations (2834)	463372526

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1602263	Vhcp Management Ii, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1602264	Venrock Healthcare Capital Partners Ii, L.p.	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1615979	Y Bong Koh	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1615983	Vhcp Co-Investment Holdings Ii, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1698082	P Nimish Shah	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1738048	Venrock Healthcare Capital Partners Iii, L.p.	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1738053	Vhcp Management Iii, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1750761	Vhcp Co-Investment Holdings Iii, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1808512	Venrock Healthcare Capital Partners Eg, L.p.	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No
1808518	Vhcp Management Eg, Llc	C/O Venrock 3340 Hillview Avenue Palo Alto CA 94304	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-10-18	40,400	$11.98	9,891,480	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2022-10-19	241,366	$10.29	10,132,846	No	4	P	Indirect	By Funds
Common Stock	Acquisiton	2022-10-19	70,100	$11.25	10,202,946	No	4	P	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Funds
No	4	P	Indirect	By Funds
No	4	P	Indirect	By Funds

Footnotes

Consists of (i) 10,621 shares purchased by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (ii) 1,062 shares purchased by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (iii) 28,717 shares purchased by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.97 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein.
The shares purchased on October 19, 2022 consist of (i) 81,884 shares purchased by VHCP III, (ii) 8,192 shares purchased by VHCP Co-3 and (iii) 221,390 shares purchased by VHCP EG.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.